Cathy Eng
#158,242
Most Influential Person Now
Researcher
Cathy Eng's AcademicInfluence.com Rankings
Cathy Engengineering Degrees
Engineering
#6716
World Rank
#8053
Historical Rank
Electrical Engineering
#2038
World Rank
#2141
Historical Rank
Applied Physics
#2200
World Rank
#2239
Historical Rank
Download Badge
Engineering
Cathy Eng's Degrees
- Masters Electrical Engineering Stanford University
- Bachelors Chemical Engineering University of California, Berkeley
Why Is Cathy Eng Influential?
(Suggest an Edit or Addition)Cathy Eng's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. (2006) (1216)
- Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. (2009) (1176)
- Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases (2005) (1051)
- EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. (2008) (912)
- Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. (2000) (799)
- Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. (2008) (551)
- A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group (2020) (528)
- Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. (2010) (464)
- Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. (2012) (411)
- American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. (2010) (408)
- Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin‐based chemotherapy for colorectal liver metastases (2007) (392)
- Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. (1999) (389)
- High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. (2011) (348)
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (345)
- Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. (2000) (335)
- Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer (2007) (307)
- Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. (2017) (287)
- Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. (2000) (286)
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. (2019) (282)
- Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. (2000) (279)
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. (2015) (206)
- Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. (2009) (203)
- Molecular identification of latent precancers in histologically normal endometrium. (2001) (203)
- A novel platform for detection of CK+ and CK- CTCs. (2011) (195)
- Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. (2001) (189)
- Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. (2010) (189)
- Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes (2017) (186)
- Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005 (2011) (181)
- Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. (2010) (180)
- Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. (2007) (168)
- Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer (2006) (159)
- Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival (2007) (157)
- Management of bevacizumab-associated bowel perforation: a case series and review of the literature. (2008) (157)
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper (2020) (153)
- Changes in endometrial PTEN expression throughout the human menstrual cycle. (2000) (150)
- SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma (2012) (149)
- Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. (2015) (144)
- Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer (2012) (139)
- Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer (2015) (130)
- Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. (2006) (126)
- The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer (2013) (113)
- Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers (2017) (109)
- Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. (2014) (108)
- Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. (2014) (107)
- Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. (2007) (107)
- Epidemiology, staging, and screening of head and neck cancer. (2003) (106)
- Antiemetics: ASCO Guideline Update. (2020) (105)
- Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin (2010) (104)
- Long‐term quality of life after radiotherapy for the treatment of anal cancer (2010) (101)
- Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative (2015) (101)
- Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer (2010) (99)
- Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases (2017) (99)
- Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer (2014) (95)
- Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer (2016) (95)
- The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal (2014) (93)
- Practical application of a calculator for conditional survival in colon cancer. (2009) (89)
- Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis. (2006) (88)
- Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial (2014) (83)
- Metformin use and improved response to therapy in rectal cancer (2013) (83)
- American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. (2016) (83)
- Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification (2018) (82)
- Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer (2010) (82)
- The current landscape of locally advanced rectal cancer (2011) (81)
- Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix: The Prognostic Impact of Histological Grade (2013) (81)
- Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer (2019) (80)
- Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity (2012) (80)
- Association between KRAS mutation and lung metastasis in advanced colorectal cancer (2014) (75)
- Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome (2009) (73)
- Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors (2005) (73)
- Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients (2012) (72)
- Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer: Outcomes and Toxicity (2014) (71)
- Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer (2017) (69)
- Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (2014) (66)
- Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. (2012) (66)
- Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer (2009) (64)
- Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI‐GI) (2010) (63)
- Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C (2009) (60)
- International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. (2020) (59)
- Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. (2008) (58)
- Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation (2010) (58)
- Cetuximab in the treatment of patients with colorectal cancer (2011) (57)
- Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. (2009) (56)
- Number of lymph nodes examined and prognosis among pathologically lymph node‐negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma (2011) (56)
- Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy (2012) (54)
- Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. (2017) (54)
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma (2018) (54)
- A Twenty-Year Experience with Adenocarcinoma of the Anal Canal (2009) (53)
- A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. (2014) (52)
- The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. (2010) (51)
- A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type KRAS who have received first‐line systemic therapy (2016) (50)
- Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal (2017) (50)
- Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence‐free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy (2013) (50)
- Metastasis regulation by PPARD expression in cancer cells. (2017) (49)
- FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma (2017) (49)
- A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. (2004) (49)
- Randomized controlled trial of neurofeedback on chemotherapy‐induced peripheral neuropathy: A pilot study (2017) (49)
- Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC). (2012) (48)
- Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. (2014) (47)
- MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon (2016) (47)
- GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. (2012) (47)
- Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up (2016) (47)
- Global and targeted serum metabolic profiling of colorectal cancer progression (2017) (45)
- Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response (2015) (42)
- Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. (2018) (41)
- Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results–Medicare data, 1998‐2007 (2014) (41)
- Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer (2015) (40)
- Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial (2007) (40)
- Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin (2016) (40)
- Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer (2017) (39)
- Anal Cancer: Current and Future Methodology (2006) (39)
- A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. (2011) (39)
- Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. (2017) (39)
- Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. (2013) (38)
- A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced Biliary Tree Carcinoma (2004) (37)
- Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction (2016) (35)
- Prognostic factors for squamous cell cancer of the anal canal. (2008) (35)
- Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (2018) (34)
- Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab. (2007) (33)
- Impact of multimodal therapy in locally recurrent rectal cancer (2016) (33)
- The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. (2016) (33)
- The promise of mTOR inhibitors in the treatment of colorectal cancer (2012) (32)
- Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. (2012) (32)
- Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer (2019) (31)
- Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer (2011) (31)
- The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. (2018) (31)
- Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. (2008) (31)
- Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. (2016) (30)
- Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms (2015) (29)
- Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. (2008) (28)
- A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5‐fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver (2010) (28)
- Association of primary (1{degrees}) site and molecular features with progression-free survival (PFS) and overall survival (OS) of metastatic colorectal cancer (mCRC) after anti-epidermal growth factor receptor ({alpha}EGFR) therapy. (2016) (28)
- Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. (2015) (28)
- Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer (2016) (27)
- Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. (2018) (27)
- Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab (2019) (26)
- Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection (2017) (26)
- Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). (2006) (25)
- Long‐term results of weekly/daily cisplatin‐based chemoradiation for locally advanced squamous cell carcinoma of the anal canal (2013) (25)
- Epidermal growth factor receptor inhibition in metastatic anal cancer (2016) (25)
- Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. (2009) (25)
- NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). (2016) (25)
- A randomized, placebo-controlled, phase I/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. (2013) (24)
- Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. (2020) (24)
- Mode effects in the center for epidemiologic studies depression (CES-D) scale: personal digital assistant vs. paper and pencil administration (2007) (24)
- Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum (2012) (23)
- Clinical utility of circulating cell-free DNA in advanced colorectal cancer (2017) (23)
- Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk. (2020) (23)
- First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. (2017) (23)
- Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. (2012) (22)
- Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival (2017) (22)
- Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck (2004) (21)
- Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. (2007) (20)
- Are Herbal Medicines Ripe for the Cancer Clinic? (2010) (20)
- Oral fluoropyrimidine treatment of colorectal cancer. (2001) (20)
- 403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer (2020) (20)
- A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. (2020) (20)
- A phase II study of capecitabine and concomitant boost radiotherapy (XRT) in patients (pts) with locally advanced rectal cancer (LARC) (2005) (19)
- Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). (2014) (19)
- Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors. (2001) (19)
- Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. (2017) (18)
- Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. (2019) (18)
- Fatal diffuse alveolar damage associated with oxaliplatin administration. (2011) (18)
- Treatment Options in Metastatic Squamous Cell Carcinoma of the Anal Canal (2008) (18)
- Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. (2018) (18)
- Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. (2014) (17)
- Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. (2008) (16)
- Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis (2017) (16)
- Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab (2017) (16)
- Chemotherapy and radiation of anal canal cancer: the first approach. (2004) (16)
- Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. (2018) (16)
- Phase II trial of neoadjuvant bevacizumab (BEV), capecitabine (CAP), and radiotherapy (XRT) for locally advanced rectal cancer (2008) (16)
- A comprehensive framework for early-onset colorectal cancer research. (2022) (16)
- Allelic loss of 10q23, the PTEN tumour suppressor gene locus, in Barrett's oesophagus-associated adenocarcinoma (2001) (15)
- Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC). (2006) (15)
- Measurement of DNA damage in peripheral blood by the γ-H2AX assay as predictor of colorectal cancer risk. (2017) (15)
- Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC) (2005) (14)
- Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma (2014) (14)
- Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation (2016) (14)
- Minocycline for Symptom Reduction during Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. (2019) (14)
- Efficacy of chemotherapy after treatment with regorafenib in metastatic colorectal cancer (mCRC). (2015) (14)
- Transthoracic Port Placement Increases Safety of Total Laparoscopic Posterior Sectionectomy (2016) (13)
- Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma (2017) (13)
- A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer (2020) (13)
- Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy (2017) (13)
- Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case‐only analysis (2010) (13)
- Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy (2017) (13)
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline (2022) (13)
- Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus. (2015) (12)
- Colorectal Cancer: Diagnosis and Clinical Management (2014) (12)
- InterAACT: An international multicenter open label randomized phase II advanced anal cancer trial comparing cisplatin (CDDP) plus 5-fluorouracil (5-FU) versus carboplatin (CBDCA) plus weekly paclitaxel (PTX) in patients with inoperable locally recurrent (ILR) or metastatic disease. (2015) (12)
- Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN). (2004) (12)
- Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (2007) (12)
- Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). (2020) (12)
- The Management and Prevention of Anal Squamous Cell Carcinoma. (2019) (11)
- Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. (2014) (11)
- Physician interpretation of genomic test results and treatment selection (2018) (11)
- Multidetector Computed Tomography Follow-up of Hypoattenuating Small Liver Lesions in Patients With Rectal Cancer (2011) (11)
- A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group. (2017) (11)
- Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. (2018) (11)
- Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery (2017) (10)
- Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma (2019) (10)
- Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer. (2010) (10)
- Phase II trial of temsirolimus (CCI-779) in patients with relapsed or refractory multiple myeloma (MM): Preliminary results. (2006) (10)
- Exploratory analysis of adjuvant chemotherapy benefits after preoperative chemoradiotherapy and radical resection for rectal cancer. (2012) (10)
- Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery (2018) (10)
- Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma (2012) (10)
- First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer (2021) (10)
- Atypical metastatic presentations in colorectal cancer: a case series. (2014) (10)
- Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer (2006) (10)
- Cisplatin (C) based chemoradiation (CXRT) for locally advanced squamous cell carcinoma (SCCA) of the anal canal (AC): A 20-year perspective. (2011) (9)
- Southwest Oncology Group 0408: Phase II trial of neoadjuvant capecitabine/oxaliplatin/bevacizumab for resectable colorectal metastases in the liver. (2006) (9)
- Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. (2008) (9)
- Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation (2021) (9)
- Improving the AJCC/TNM staging for adenocarcinomas of the appendix: The prognostic impact of histologic grade. (2012) (9)
- POLE mutations in colorectal cancer: a new biomarker? (2016) (9)
- Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies (2018) (9)
- Neoadjuvant Strategies: Locally Advanced Rectal Cancer (2017) (9)
- Pharmacotherapy of Anal Cancer (2017) (8)
- Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy (2020) (8)
- Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) (2022) (8)
- Genomic analysis and selected molecular pathways in rare cancers (2012) (8)
- Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery (2017) (8)
- The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients (2020) (8)
- Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. (2016) (8)
- K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. (2008) (8)
- Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. (2013) (8)
- The Current State of Targeted Agents in Rectal Cancer (2012) (8)
- Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. (2020) (8)
- Optimal management of squamous cell carcinoma of the anal canal: where are we now? (2014) (7)
- Current treatment and future directions in the management of anal cancer (2021) (7)
- Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm (2017) (7)
- Role of the MET–HGF axis in colorectal cancer: precepts and prospects (2012) (7)
- Cetuximab in Refractory Squamous Cell Carcinoma of the Anal Canal (2014) (7)
- Frequency of concurrent gene mutations and copy number alterations in circulating cell-free DNA (cfDNA) from refractory metastatic CRC patients. (2014) (7)
- Validation of neoadjuvant rectal cancer (NAR) score as a surrogate endpoint for overall survival in real-life practice settings. (2018) (7)
- Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer (2020) (7)
- The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program (2013) (7)
- Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study (2015) (7)
- Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. (2015) (7)
- Neoadjuvant Chemoradiation with Capecitabine Versus Infusional 5-fluorouracil (5-FU) for Locally Advanced Rectal Cancer: A Matched Pair Analysis (2005) (7)
- Metastatic Anal Cancer and Novel Agents. (2017) (7)
- Emerging drugs for colorectal cancer. (2008) (7)
- Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer (2022) (7)
- Optimal Treatment Strategies for Anal Cancer (2014) (6)
- A randomized, phase I/II trial of AMG 102 or AMG 479 in combination with panitumumab (pmab) compared with pmab alone in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Safety and efficacy results. (2011) (6)
- Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer (2020) (6)
- The characteristics of ARID1A mutations in colorectal cancer. (2018) (6)
- Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses (2005) (6)
- Evolution of Cancer Care in Response to the COVID‐19 Pandemic (2020) (6)
- Panitumumab (pmab) plus AMG 102 in patients (pts) with wild-type KRAS metastatic colorectal cancer (mCRC): Updated safety results. (2010) (6)
- Quality of life after intensity-modulated radiation therapy for anal cancer (2015) (6)
- The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. (2011) (6)
- Colon, Rectal, and Anal Cancer Management (2006) (6)
- BRAF Mutation in Colorectal Cancer: An Enigmatic Target. (2021) (6)
- A randomized, double-blinded, placebo-controlled trial of oral alpha lipoic acid to prevent platinum-induced polyneuropathy. (2011) (6)
- Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. (2018) (6)
- Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016 (2022) (6)
- Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset (2020) (6)
- Delayed Presentation of DPD Deficiency in Colorectal Cancer (2014) (5)
- Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma (2020) (5)
- Survival advantage associated with metformin usage in patients with colorectal cancer (CRC) and type II noninsulin-dependent diabetes (NIDDM). (2011) (5)
- Experimental and investigational drugs for the treatment of anal cancer (2018) (5)
- Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients (2021) (5)
- Yttrium microspheres with cetuximab plus irinotecan for patients with advanced colorectal cancer metastases to liver. (2010) (5)
- 537PP2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer (2017) (5)
- Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer (2020) (5)
- Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal. (2016) (5)
- A phase II study of capecitabine plus oxaliplatin and radiation therpy, XELOX-XRT, in squamous cell carcinoma (SCCA) of the anal canal: A preliminary analysis (2005) (5)
- Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience (2021) (5)
- Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal? (2009) (5)
- MD Anderson experience with off-study regorafenib in patients with advanced colorectal cancer. (2014) (5)
- Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. (2012) (5)
- A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group (2017) (5)
- The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. (2017) (5)
- LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC) (2022) (4)
- Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation (2018) (4)
- Exploratory analysis of adjuvant chemotherapy effects after preoperative chemoradiotherapy and radical resection for rectal cancer. (2012) (4)
- Emerging drugs for colorectal cancer (2008) (4)
- Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors (2020) (4)
- A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. (2019) (4)
- Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. (2012) (4)
- Systemic chemotherapy in the setting of unresectable appendiceal epithelial neoplasms (AEN). (2012) (4)
- First-inhuman trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients (2018) (4)
- Inherited Cancer Susceptibility Gene Sequence Variations Among Patients With Appendix Cancer. (2022) (4)
- Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. (2019) (4)
- Patient-reported symptoms from patients with advanced pancreatic cancer undergoing gemcitabine-based chemotherapy. (2012) (4)
- Age-standardised incidence rate and epidemiology of colorectal cancer in Africa: a systematic review and meta-analysis (2022) (4)
- Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection (2017) (3)
- 482 Relationship Between Tumor MET Expression and Clinical Outcomes in Cancer Patients Treated with Tivantinib (2012) (3)
- FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. (2021) (3)
- Early-Onset Colorectal Cancer: The Mystery Remains. (2021) (3)
- Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy (2012) (3)
- Histologic and Racial/Ethnic Patterns of Appendiceal Cancer among Young Patients (2021) (3)
- Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). (2014) (3)
- Microbiome Dynamics During Chemoradiotherapy for Anal Cancer. (2022) (3)
- Impact of microsatellite instability (MSI) on tumor clonal evolution in metastatic colorectal cancer (mCRC). (2018) (3)
- Emerging transcriptional landscape and putative therapeutic targets in young patients with metastatic colorectal cancer (CRC). (2015) (3)
- More questions regarding HIPEC in colorectal carcinomatosis. (2019) (3)
- Delphi initiative for early-onset colorectal cancer (DIRECt). International Management Guidelines. (2022) (3)
- Impact of PI3K aberrations on efficacy of perifosine (P), x-PECT: A phase III randomized study of P plus capecitabine (PC) versus placebo plus capecitabine (C) in refractory metastatic colorectal cancer (mCRC) patients. (2014) (3)
- Association of CpG island methylator phenotype (CIMP) with inferior progression-free survival with anti-EGFR monoclonal antibody therapy in metastatic colorectal cancer. (2014) (3)
- Neoadjuvant Chemotherapy for Colon Cancer (2020) (3)
- Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. (2007) (3)
- Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101. (2021) (3)
- Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study. (2019) (3)
- Safety considerations with new treatment regimens for anal cancer (2021) (3)
- Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required (2019) (3)
- Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. (2021) (3)
- Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC) (2004) (3)
- Carcinoma of the anal canal: small steps in treatment advances. (2011) (3)
- Is the neutrophil-lymphocyte ratio (NLR) a predictive and prognostic factor in rectal cancer patients treated with neoadjuvant chemoradiation (nCRT)? (2016) (3)
- Circulating DNA biomarkers: a primer for metastatic colorectal cancer? (2015) (3)
- The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies (2022) (3)
- Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience. (2012) (2)
- Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer. (2011) (2)
- A phase II study of durvalumab (MEDI4736) (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). (2020) (2)
- Clinical and pathologic factors associated with survival in BRAFV600E colorectal cancers. (2020) (2)
- Short-Course Radiation As a Component of Definitive Multidisciplinary Treatment for Select Patients with Metastatic Rectal Adenocarcinoma (2017) (2)
- Randomized trial of a home-based exercise intervention for patients with advanced colorectal cancer: Effects on physical functioning and activity levels. (2015) (2)
- FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. (2020) (2)
- Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. (2012) (2)
- Abstract CT131: NCI#9673 phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal: Immunologic correlates of response (2016) (2)
- Colorectal cancer during pregnancy or postpartum: Case series and literature review (2021) (2)
- Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series (2013) (2)
- (S021) A Phase 2 Randomized Double Blinded Study Evaluating the Efficacy of Curcumin With Pre-Operative Chemoradiation for Rectal Cancer (2017) (2)
- A systematic review of surrogate endpoints (SEPs) for overall survival (OS) in metastatic colorectal cancer (mCRC). (2019) (2)
- Phase II study of capecitabine and radiotherapy (RT) plus concomitant boost in patients (pts) with locally advanced rectal cancer (LARC). (2004) (2)
- Challenges of efficacy assessments in pseudomyxoma peritonea. (2015) (2)
- Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. (2007) (2)
- MET overexpression as a hallmark of the epithelial-mesenchymal transition (EMT) phenotype in colorectal cancer. (2013) (2)
- CEA as a blood-based biomarker in anal cancer (2021) (2)
- FRESCO-2: A global phase III study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC). (2021) (2)
- Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. (2016) (2)
- Biological agents versus chemotherapy in the treatment of colorectal cancer (2006) (2)
- Commentary: practice patterns and potential impact on quality measures for a practicing physician. (2009) (2)
- Neoadjuvant treatment response and outcomes in locally advanced rectal cancer: Establishing oncologic benchmarks. (2011) (2)
- a novel Platform for Detection of cK 1 and cK 2 cTcs (2011) (2)
- Anal Cancer: Emerging Standards in a Rare Rare Disease. (2022) (2)
- Anal Canal Cancers (2017) (2)
- Clinical relevance of cytokeratin-negative circulating tumor cells. (2011) (1)
- What determines adjuvant chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer? (2012) (1)
- Gastrointestinal Oncology: A Practical Guide (2012) (1)
- Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report. (2022) (1)
- Perspectives on clinical trials for gastrointestinal malignancies. (2015) (1)
- Pharmacotherapeutic considerations for elderly patients with colorectal cancer (2019) (1)
- Correlation of single nucleotide polymorphisms (SNPs) of hypoxia-related genes with pathologic complete response (pCR) following neoadjuvant chemoradiation (chemoXRT) for locally advanced rectal cancer. (2010) (1)
- Cancer of the anal region (2015) (1)
- Prospective study of paresthetic neurotoxicity from oxaliplatin-based regimens in the treatment of colorectal cancer. (2010) (1)
- Colorectal Cancer Genomics by Genetic Ancestry. (2022) (1)
- Considerations in the management of younger patients With colorectal cancer: Q&A. (2021) (1)
- BRAF V600E mutated metastatic colorectal cancer: current progress and future directions (2021) (1)
- Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response. (2014) (1)
- The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix. (2013) (1)
- Effect of bevacizumab on rate of oxaliplatin-induced thrombocytopenia and splenomegaly. (2012) (1)
- (552) Neurofeedback to treat chemotherapy-induced peripheral neuropathy (CIPN). (2016) (1)
- Feasibility of using home-based mobile sensors for remote patient monitoring in cancer care and prevention. (2014) (1)
- Prognostic impact of baseline CEA level and surgery of primary tumor among patients with stage IV denovo colon cancer. (2011) (1)
- A phase II randomized double blinded trial evaluating the efficacy of curcumin with pre-operative chemoradiation for rectal cancer (2022) (1)
- Comprehensive Genomic Pro fi ling of Metastatic Squamous Cell Carcinoma of the Anal Canal (2017) (1)
- Association of human papillomavirus with unique clinicopathologic features in patients with metastatic squamous cell carcinoma of the anal canal. (2014) (1)
- Somatic mutations in young-onset colorectal cancer unrelated to hereditary syndromes: A comparative study using high-depth targeted exome sequencing. (2015) (1)
- O-022A multi-institutional phase 2 study of single agent nivolumab in previously treated metastatic squamous cell carcinoma of the anal canal (SCCA) (2016) (1)
- Multidisciplinary management of stage IV colon cancer (2016) (1)
- BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers. (2014) (1)
- Considerations in the management of younger patients with colorectal cancer. (2021) (1)
- Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al (2020) (1)
- Predictors of clonal evolution in metastatic colorectal cancer patients. (2015) (1)
- A Prospective Randomized Crossover Trial of Systemic Chemotherapy in Patients with Low-Grade Mucinous Appendiceal Adenocarcinoma (2022) (1)
- Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to, "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic". (2020) (1)
- Comprehensive genomic profiling of appendiceal adenocarcinoma. (2018) (1)
- Post-treatment surveillance in locally advanced squamous cell carcinoma (SCCA) of the anal canal: A global subspecialist survey. (2016) (1)
- Pancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes? (2021) (1)
- Use of bevacizumab to reduce the rate of oxaliplatin-induced thrombocytopenia and splenomegaly. (2012) (1)
- A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer (2022) (1)
- A pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy (CIPN). (2019) (1)
- Assessment of the impact of systemic chemotherapy (SC) on the quality of life (QOL) in patients with metastatic unresectable appendiceal epithelial neoplasms (AEN). (2013) (1)
- PRIMARY ANALYSIS AND BIOMARKER EVALUATION: RANDOMIZED PHASE IB/II STUDY OF RILOTUMUMAB (AMG 102) OR GANITUMAB (AMG 479) WITH PANITUMUMAB VERSUS PANITUMUMAB ALONE IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) (2011) (1)
- Clinical and pathologic predictors of locoregional recurrence (LR), distant metastasis (DM) and overall survival (OS) in patients treated with chemoradiation and mesorectal excision for locally advanced rectal cancer (2005) (1)
- Impact of preoperative radiation dose escalation on pathologic outcomes and radiation toxicity in locally advanced rectal cancer (LARC): A matched-pair analysis. (2011) (1)
- Retrospective RAS analysis of the EPIC trial: Cetuximab plus irinotecan vs irinotecan in patients (pts) with second-line metastatic colorectal cancer (mCRC). (2018) (1)
- RAS heterogeneity as a prognostic marker in metastatic colorectal cancer. (2017) (1)
- Tumor microsatellite-instability status to predict benefit of adjuvant chemotherapy for stage III colon cancer (2007) (1)
- Variation in Treatment Patterns of Patients with Early-Onset Gastric Cancer (2022) (1)
- Feasibility of Mobile and Sensor Technology for Remote Monitoring in Cancer Care and Prevention (2021) (1)
- CEA as a pharmacodynamic biomarker for metastatic anal cancer. (2018) (1)
- The treatment of colorectal carcinoma: standard chemotherapy and beyond. (2004) (1)
- PD-0018 Phase I/II Study of Tivantinib (ARQ 197) Irinotecan, and Cetuximab in Patients with Kras Wildtype, Previously Treated, Metastatic Colorectal Cancer (2012) (1)
- A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer. (2012) (1)
- Abstract 5584: BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (IdyllaTM) (2014) (1)
- Corrigendum: Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer (Annals of Oncology (2018) 29 (139-144) DOI: 10.1093/annonc/mdx688) (2019) (1)
- Antibody-independent isolation and characterization of circulating tumor cells using dielectrophoresis: Fluid flow fractionation in metastatic colorectal cancer. (2016) (1)
- Racial/ethnic and sex differences in somatic cancer gene mutations among patients with early-onset colorectal cancer. (2022) (1)
- Inflammatory marker levels and prediction of patient-reported symptoms in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. (2014) (1)
- Microbiome Dynamics During Chemoradiotherapy for Anal Cancer (2021) (1)
- Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal adenocarcinoma: A phase I trial. (2012) (1)
- Is there a role for neoadjuvant chemotherapy in the management of non-carcinoid epithelial neoplasms of the appendix? (2007) (1)
- TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer? (2020) (1)
- Long-term Quality of Life after Chemoradiation for Anal Cancer (2008) (1)
- Emerging role of immunotherapy in the treatment naïve metastatic colorectal cancer patient (2020) (1)
- Abstract 101: Racial differences in somatic mutations among patients with early-onset colorectal cancer (2021) (1)
- Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. (2021) (1)
- The role of partial splenic embolization (PSE) in the management of chemotherapy-induced thrombocytopenia. (2012) (1)
- Phase I Trial of Preoperative Radiation Therapy with Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Adenocarcinoma (2011) (1)
- Clinicopathologic features of KRAS-mutated colorectal tumors vary by site of mutation. (2013) (1)
- M. D. Anderson Symptom Inventory--Gastrointestinal Module (2015) (0)
- Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor. (2013) (0)
- Squamous Cell Carcinoma of the Anal Canal (2019) (0)
- Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. (2020) (0)
- Erratum: A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma (American Journal of Clinical Oncology (December 2004) 27, 6 (505-509)) (2005) (0)
- Long-Term results of weekly/daily cisplatin-Based chemoradiation for locally advanced squamous cell carcinoma of the anal canal (2014) (0)
- Female sex and standardized mitomycin-c dose are associated with increased risk of neutropenia after hyperthermic intraperitoneal chemotherapy (2007) (0)
- CHFR methylation as an epigenetic marker for recurrence of colon cancer. (2009) (0)
- Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2022) (0)
- Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons? (2019) (0)
- The impact on patient management of whole-body FDG-PET scanning in patients with liver metastases from colorectal carcinoma. (2004) (0)
- Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response (2015) (0)
- Association of prior treatment with anti-EGFR monoclonal antibodies with downregulation of circulating TRAIL and upregulation of EGFR and VEGF family ligands in metastatic colorectal cancer. (2014) (0)
- Colorectal Cancer Survivorship Management (2015) (0)
- Abstract 4742:APCWT/RASWT/BRAFWTtumors represent an under recognized poor prognostic group of right sided colorectal cancer (2017) (0)
- Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2015) (0)
- Phase I study of DFP-11207, a novel oral 5-FU with enhanced PK and improved tolerability, in patients with solid tumors. (2019) (0)
- Reporting of patient (pt) characteristics (c) and use of stratification factors (SF) in phase III trials for metastatic colorectal cancer (mCRC): Urgent need for standardization. (2019) (0)
- Will PICCOLO affect metastatic colorectal cancer therapy? (2013) (0)
- Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies. (2015) (0)
- Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. (2018) (0)
- Managing Non-Hepatic Metastatic Sites: Lung and CNS (2019) (0)
- Latest Developments in the Treatment of Anal Cancer (2017) (0)
- Utilization and cost of CPT-11 (C) in elderly previously treated metastatic colorectal cancer (MCRC) patients (pts) (2004) (0)
- 125PTargeted methylation sequencing of plasma cell-free DNA identifies patients with advanced breast, colorectal, non-small cell lung cancer, melanoma with poor outcomes (2017) (0)
- Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response. (2023) (0)
- Colorectal Cancer (2018) (0)
- Prognostic and predictive effect of COX-2 expression in appendiceal adenocarcinomas. (2012) (0)
- Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer (2012) (0)
- Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. (2019) (0)
- Survival outcomes used to generate version 9 American Joint Committee on Cancer staging system for anal cancer. (2023) (0)
- Imaging, Diagnosis, Prognosis Association of CHFR Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer (2011) (0)
- Survival advantage associated with palliative oophorectomy in patients with metastatic colorectal cancer (CRC) to the ovaries (mCRC-O): A single institution retrospective analysis. (2011) (0)
- Issue Information (2022) (0)
- Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. (2021) (0)
- Immunotherapy in Localized Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care? (2023) (0)
- A prospective biomarker trial of microbiome, immune, and genomic markers as predictors of radiation response in anal squamous cell carcinoma. (2018) (0)
- Examining the increase in colorectal cancer in younger patients. (2021) (0)
- Retrospective evaluation of patients with colorectal cancer (CRC) and type II non-insulin-dependent diabetes (NIDDM). (2011) (0)
- A phase 1b/2, open-label study of amivantamab monotherapy or in combination with standard-of-care chemotherapy in participants with advanced or metastatic colorectal cancer. (2023) (0)
- Abstract A93: Genetic variations in aging related genes/pathways and colorectal cancer risk (2012) (0)
- Abstract 4263: Concurrent aberrations in the Wnt, MAPK and PI3K pathways identified through next generation sequencing of relapsed refractory colorectal adenocarcinoma (CRC): Implications for future therapeutic trials (2015) (0)
- Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer (2012) (0)
- Clinical utility of a circulating cell-free DNA assay for clinical trial enrollment in refractory metastatic colorectal cancer patients. (2015) (0)
- OP-JNCI210126 1..3 (2021) (0)
- A Bi-institutional Experience of Definitive Chemoradiation Therapy for Treatment of Anal Cancer Involving the Para-aortic Lymph Nodes (2017) (0)
- Effect of minocycline on symptom burden and inflammation markers in patients with colorectal cancer: A randomized phase II trial. (2018) (0)
- Is the presence of acellular mucin in rectal cancer patients with a pathologic complete response to preoperative chemoradiation of prognostic significance (2008) (0)
- Updated analysis: Effect of biweekly dosing schedule of trifluridine-tipiracil (TAS-102) on rates of myelosuppression and maintenance of therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). (2023) (0)
- Meat consumption and BRAF mutation status in colorectal cancer. (2019) (0)
- CO.28: Neoadjuvant Chemotherapy, Excision and Observation (NEO) for early rectal cancer. (2019) (0)
- Multimodal salvage therapy for locally recurrent and re-recurrent rectal cancer. (2010) (0)
- The use of biologic therapy in the treatment of unresectable appendiceal neoplasms (2008) (0)
- Oncologic and functional hazards of obesity among patients with locally advanced rectal cancer. (2011) (0)
- Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC). (2016) (0)
- Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers. (2017) (0)
- Colorectal cancer adjuvant chemotherapy trends among a nonelderly veteran cohort at a southern veterans health administration (2021) (0)
- Role of biologic therapy in the treatment of unresectable appendiceal epithelial neoplasms (AEN). (2012) (0)
- Temporal trends in receipt of adjuvant chemotherapy for veterans with colorectal cancer. (2020) (0)
- FOLFOXIRI versus doublet-regimens in the first-line therapy of MSI-S right-sided (RS) metastatic colorectal cancer (mCRC): A survival analysis. (2019) (0)
- Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). (2016) (0)
- In Reply (2020) (0)
- 1067 : Predictors of Tumor Response and Downstaging in Patients Treated with Preoperative Chemoradiation for Rectal Cancer (2006) (0)
- 5. Colorectal Cancer (2012) (0)
- TITLE: Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer (2019) (0)
- Biologics in rectal cancer (2022) (0)
- Colorectal Polyps and Cancers: A Multidisciplinary Approach (2012) (0)
- ASCO GI: Latest Treatments and Research in Gastrointestinal Cancers (2013) (0)
- A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy (2022) (0)
- Association of PTEN loss and local recurrence in stage II-III colon cancer. (2011) (0)
- Self-report of neuropathy from oxaliplatin-based regimens in the treatment of colorectal cancer: With or without bevacizumab. (2011) (0)
- Number of lymph nodes examined and prognosis among pathologically node-negative patients after preoperative chemoradiation for rectal cancer. (2010) (0)
- Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups and to reflect prognosis. (2015) (0)
- Patterns of failure and outcomes in anal adenocarcinoma. (2006) (0)
- Contemporary Evidence-Based Management of Newly Diagnosed Metastatic Colorectal Cancer (2015) (0)
- Outcomes Following Hyperfractionated Accelerated Reirradiation for Recurrent Anal Cancer (2016) (0)
- BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC). (2023) (0)
- Abstract 2782: Risk loci for a breast-colon cancer phenotype: results from a genome-wide association study (2015) (0)
- S1113 Is There a Correlation Between Body Mass Index (BMI) and Endoscopic Ultrasound (EUS) Stage of Rectal Cancer at Initial Presentation (2010) (0)
- The association between female hormonal supplementation and molecular types in colorectal cancer. (2019) (0)
- “New” Drugs in Localized Rectal Cancer (2015) (0)
- Immunotherapy for GI Cancers (2021) (0)
- sTNF-R1 and other cytokines associated with symptom burden related to chemotherapy in patients with colorectal cancer (2011) (0)
- Impact of multidisciplinary therapy on high-grade appendiceal adenocarcinoma (AA). (2013) (0)
- Session 2: Mutational discordance: the big challenge in personalized treatments – any solutions? (2018) (0)
- Utilization and cost of CPT-11 (C) in elderly previously treated metastatic colorectal cancer (MCRC) patients (pts). (2004) (0)
- Supportive care (SC) utilization for patients with locally advanced pancreatic cancer: Review of the National Cancer Data Base (2004-2018). (2022) (0)
- Proteomic features of colorectal cancer independently predict relapse-free survival. (2015) (0)
- Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors (2023) (0)
- Abstract C50: Phase I dose escalation study of the oral multi-kinase VEGF inhibitor regorafenib and the anti-EGFR monoclonal antibody cetuximab in patients with advanced solid tumors including colorectal cancer (2015) (0)
- O3-5-4Phase I study of DFP-11207, a novel chemotherapeutic agent, in patients with solid tumors by reasonable dose escalation (2016) (0)
- Inflammatory cytokines and toxic effects of oxaliplatin-based chemotherapy in patients with colorectal cancer. (2011) (0)
- Identification of actionable genomic alterations utilizing cfDNA. (2018) (0)
- Current and emerging trends in the treatment of metastatic colorectal cancer (2007) (0)
- Carcinoma of the rectum. A retrospective analysis from Singapore. (1983) (0)
- Identification of polymorphisms in ultraconserved elements (UCEs) associated with clinical outcomes in patients (pts) with stage II/III colorectal cancer (CRC). (2011) (0)
- Abstract 5236: Prospective clinical application of circulating cell-free DNA sequencing in metastatic colorectal cancer (2015) (0)
- Prognostic value of genomic alterations (GA) on overall survival in appendiceal adenocarcinoma (AA). (2019) (0)
- Abstract 5607: BRAF and KRAS mutation testing in plasma cell-free DNA with ICE COLD-PCR in patients with advanced cancers (2014) (0)
- Abstract 1553: Redefining CTCs: Detection of cytokeratin-negative circulating tumor cells (CTCs) (2011) (0)
- 418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors (2020) (0)
- The impact on patient management of whole-body FDG-PET scanning in patients with liver metastases from colorectal carcinoma (2004) (0)
- Systemic therapy for appendiceal cancer (2015) (0)
- Proteomic signatures of colorectal cancer to identify distinct and reproducible subgroups independent of oncogenic mutations. (2015) (0)
- Interplay of grade and stage on survival outcomes in appendiceal adenocarcinoma: Corroboration of the AJCC (8th edition) Cancer Staging Classification. (2018) (0)
- The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer. (2007) (0)
- Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer (2023) (0)
- Building on the foundation of 5-FU to treat metastatic colorectal cancer (2008) (0)
- Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study. (2023) (0)
- Abstract 3739: Are young adults with colorectal cancer doing enough to stay healthy (2015) (0)
- Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution (2022) (0)
- Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. (2008) (0)
- Hyperfractionated Accelerated Reirradiation for Rectal Cancer: A Large Single-Institution Retrospective Analysis (2016) (0)
- Longitudinal trajectory of cancer survivorship in patients with recurrent rectal cancer: Anatomy of recurrence in relation to quality of life and pain. (2017) (0)
- Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. (2021) (0)
- Systematic survey of therapeutic trials for metastatic colorectal cancer. (2012) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. (2014) (0)
- Quality of Life After Intensity Modulated Radiation Therapy (IMRT) for Anal Cancer (2013) (0)
- A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176). (2021) (0)
- Combined Modality Strategies in the Treatment of Head and Neck Cancer (2003) (0)
- 124. Fatigue, affective symptom burden and altered tryptophan and phenylalanine metabolism in colorectal cancer patients undergoing chemotherapy (2013) (0)
- Predictors for detecting circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC). (2018) (0)
- Abstract 493: Quantity of KRAS mutations in cell-free DNA is associated with survival of patients with advanced cancers (2016) (0)
- Reply to S. Boutayeb et al. (2020) (0)
- Impact of travel distance on timeliness of adjuvant chemotherapy in veterans with colorectal cancer. (2020) (0)
- The rate of novel actionable mutations in standard of care NGS panel testing in gastrointestinal malignancies. (2018) (0)
- Multiple independent methods fail to confirm MET amplification rate reported in literature for metastatic colorectal cancer (mCRC). (2015) (0)
- Impact of the timing of hepatitis B virus (HBV) identification and anti-HBV therapy initiation on the risk of adverse liver outcomes in patients receiving cancer therapy. (2017) (0)
- Preoperative chemotherapy prior to pulmonary metastatecomy in patients with prior surgically resected primary colorectal carcinoma. (2013) (0)
- Colorectal Cancer (2018) (0)
- Abstract 4260: Molecular imaging of glutamine (Gln) metabolism in RAS wildtype (WT) metastatic colorectal cancer (mCRC) (2020) (0)
- Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery (2016) (0)
- S0222 Distinct Genomic Landscape of Appendiceal Cancer Among Young Patients (2020) (0)
- Concordance of genomic alterations in anal cancer by next-generation sequencing in tissue and circulating tumor DNA. (2023) (0)
- O-0022 X-Pect Study Results: A Phase III Randomized Study of Perifosine Plus Capecitabine vs. Placebo Plus Capecitabine in Refractory mCRC Patients (2012) (0)
- Tailored multistage minimally invasive management of resectable stage IV colorectal cancer offers optimal postoperative outcomes and long-term survival: a propensity-score weighting analysis (2018) (0)
- Abstract 6696: Genomic alterations associated with early-onset and late-onset colorectal cancer (2023) (0)
- A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. (2015) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Cathy Eng?
Cathy Eng is affiliated with the following schools:
